MK-677 Evidence Guide
Ibutamoren reliably raises GH and IGF-1 and now has a recruiting Phase 3 pediatric program, but that trial has not yet established benefit. Earlier studies showed modest body-composition effects alongside appetite, edema, glucose, and heart-failure concerns. Its strongest current case is as an investigational oral option for selected pediatric growth hormone deficiency, not general performance use.
Our Take
Ibutamoren reliably raises GH and IGF-1 and now has a recruiting Phase 3 pediatric program, but that trial has not yet established benefit. Earlier studies showed modest body-composition effects alongside appetite, edema, glucose, and heart-failure concerns. Its strongest current case is as an investigational oral option for selected pediatric growth hormone deficiency, not general performance use.
- Evidence context
- Clinical research in pediatric growth hormone deficiency and oral GH-secretagogue pharmacology
- Evidence grade
- Level B
- Confidence
- Moderate
- Reference context
- Reported research reference: No approved dose; current Phase 3 dosing is protocol-controlled and indication-specific
Benefits and Evidence
- Growth Hormone and IGF-1 Elevation: Level B, includes human evidence - Consistently increases GH and IGF-1 levels to youthful ranges in elderly and GH-deficient populations, with effects sustained over months of treatment.
- Lean Body Mass: Level B, includes human evidence - Modest increases in fat-free mass observed in clinical trials, particularly in elderly and sarcopenic populations over 12 months of treatment.
- Sleep Quality: Level B, includes human evidence - Improved sleep quality with increased Stage IV (deep) sleep duration and REM sleep observed in healthy young and elderly subjects.
- Appetite Increase: Level B, includes human evidence - Significant appetite stimulation due to ghrelin receptor activation, which can be problematic for weight management but beneficial in cachexia or sarcopenia.
Side Effects and Warnings
- Increased appetite
- Water retention and edema
- Muscle pain
- Joint pain
- Elevated fasting blood glucose
- Lethargy
- Numbness and tingling in extremities
- Not FDA approved - investigational compound
Research Dosage References
- <strong>Oral</strong> - 25 mg - Once daily - Most commonly studied dose. Taken before bed to align with natural GH release patterns and minimize daytime appetite stimulation.
- <strong>Oral</strong> - 10 mg - Once daily - Lower dose used in some studies, still effective at raising IGF-1 but with fewer side effects.
Mechanism of Action
MK-677 acts as a ghrelin mimetic, binding to and activating the growth hormone secretagogue receptor type 1a (GHSR1a) in the hypothalamus and pituitary gland. This triggers growth hormone release through a mechanism distinct from GHRH, operating through the ghrelin/GHSR pathway. Activation of GHSR1a by MK-677 stimulates GH release in a pulsatile manner that preserves the natural circadian rhythm of GH secretion. The compound amplifies GH pulse amplitude without significantly affecting pulse frequency, resulting in elevated 24-hour GH profiles similar to those seen in younger individuals. The sustained elevation in GH levels leads to increased hepatic production of IGF-1, which mediates many of the anabolic and metabolic effects attributed to the GH/IGF-1 axis. Importantly, MK-677 does not suppress the hypothalamic-pituitary-adrenal axis, and cortisol levels remain largely unchanged. As a ghrelin mimetic, MK-677 also stimulates appetite through hypothalamic orexigenic pathways, which can be both a therapeutic benefit (in catabolic conditions) and a limitation (in obesity management).
Legal Status
Not FDA-approved. LUM-201 is investigational and is being studied in the recruiting Phase 3 OraGrowtH pediatric growth-hormone-deficiency trial (NCT06948214). Ibutamoren is prohibited by WADA in competitive sport under growth-hormone secretagogues.
Primary Sources
- MK-677, an orally active growth hormone secretagogue, reverses diet-induced catabolism. Journal of Clinical Endocrinology & Metabolism, 1998.
- Two-year effects of ibutamoren on muscle wasting and growth hormone levels in elderly adults. Journal of Clinical Endocrinology & Metabolism, 2008.
- Oral administration of growth hormone secretagogue MK-677 increases markers of bone turnover in healthy and functionally impaired elderly adults. Journal of Bone and Mineral Research, 1999.
- OraGrowtH: Phase 3 study of oral LUM-201 in children with idiopathic pediatric growth hormone deficiency. ClinicalTrials.gov (NCT06948214), 2026.
Quick Answers
Where is the strongest evidence for MK-677?
Ibutamoren reliably raises GH and IGF-1 and now has a recruiting Phase 3 pediatric program, but that trial has not yet established benefit. Earlier studies showed modest body-composition effects alongside appetite, edema, glucose, and heart-failure concerns. Its strongest current case is as an investigational oral option for selected pediatric growth hormone deficiency, not general performance use. Evidence context: Clinical research in pediatric growth hormone deficiency and oral GH-secretagogue pharmacology.
What are the main side effects of MK-677?
MK-677 side effects and warning signals include Increased appetite, Water retention and edema, Muscle pain, Joint pain, and Elevated fasting blood glucose.
What evidence level is MK-677?
MK-677 is rated Level B; the listed research status is Phase 3.